WO2024232368A1 - アトピー性皮膚炎の重症度の検出方法 - Google Patents
アトピー性皮膚炎の重症度の検出方法 Download PDFInfo
- Publication number
- WO2024232368A1 WO2024232368A1 PCT/JP2024/017017 JP2024017017W WO2024232368A1 WO 2024232368 A1 WO2024232368 A1 WO 2024232368A1 JP 2024017017 W JP2024017017 W JP 2024017017W WO 2024232368 A1 WO2024232368 A1 WO 2024232368A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- severity
- atopic dermatitis
- expression
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M1/00—Apparatus for enzymology or microbiology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M1/00—Apparatus for enzymology or microbiology
- C12M1/34—Measuring or testing with condition measuring or sensing means, e.g. colony counters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Definitions
- the present invention relates to a method for detecting the severity of atopic dermatitis using a marker for the severity of atopic dermatitis.
- Atopic dermatitis (hereinafter referred to as "AD") is an eczematous skin disease that mainly occurs in people with a predisposition to atopy.
- Typical symptoms of atopic dermatitis include chronic and recurrent itching, rash, erythema, etc. occurring on both sides of the body, as well as hypokeratosis, impaired barrier function, dry skin, etc.
- Most cases of atopic dermatitis occur in infants and young children, and tend to improve as the patient grows, but in recent years there has been an increase in adult-type and intractable atopic dermatitis.
- TARC blood thymus and activation-regulated chemokine
- SCCA2 squamous cell carcinoma antigen 2
- nucleic acids such as DNA and RNA in biological samples.
- Analysis using nucleic acids has the advantage that comprehensive analysis methods have been established, a wealth of information can be obtained in one analysis, and the analysis results can be easily linked functionally based on many research reports on single nucleotide polymorphisms and RNA functions.
- Nucleic acids derived from living organisms can be extracted from body fluids such as blood, secretions, tissues, etc., but it has recently been reported that RNA contained in skin surface lipids (SSL) can be used as a sample for analyzing living organisms, and that marker genes for the epidermis, sweat glands, hair follicles, and sebaceous glands can be detected from SSL (Patent Document 1). It has also been reported that marker genes for atopic dermatitis can be detected from SSL (Patent Document 2).
- SSL skin surface lipids
- Patent Document 1 International Publication No. 2018/008319
- Patent Document 2 JP 2020-74769 A
- Non-patent Document 1 Sugawara et al., Allergy (2002) 57:180-181.
- Non-patent Document 2 Ohta et al., Ann Clin Biochem. (2012) 49:277-84.
- Non-patent literature 3 Saeki et al., Journal of the Japanese Society of Dermatology (2021) 131: 2691-2777.
- the present invention relates to the following 1) and 2).
- 1) A method for measuring a gene or its expression product in a subject comprising a step of measuring the expression level of at least one gene or its expression product selected from a group of 16 genes consisting of C1QB, DIAPH1, LCE1A, CTSV, CTSZ, KRT72, SPINK5, KRT23, KLK5, LCE1B, SPRR1A, PKP1, KRT74, APRT, KRT25 and S100B in a biological sample collected from the subject in order to detect the severity of atopic dermatitis in the subject.
- a test kit for detecting the severity of atopic dermatitis used in the method of 1), comprising an oligonucleotide that specifically hybridizes with the gene or a nucleic acid derived therefrom, or an antibody that recognizes the expression product of the gene.
- the present invention relates to providing a method for measuring genes or their expression products to detect the severity of atopic dermatitis.
- the inventors collected SSL from patients with atopic dermatitis of different severity and from healthy individuals, and comprehensively analyzed the expression state of RNA contained in the SSL as sequence information. As a result, they found that the expression levels of specific genes differed significantly between patients with different severity and between patients with mild to moderate disease and healthy individuals, and that the severity of atopic dermatitis can be detected using this as an indicator.
- the present invention makes it possible to accurately and objectively detect the severity of atopic dermatitis.
- nucleic acid or “polynucleotide” means DNA or RNA.
- DNA includes cDNA, genomic DNA, and synthetic DNA
- RNA includes total RNA, mRNA, rRNA, tRNA, non-coding RNA, and synthetic RNA.
- the term "gene” refers to double-stranded DNA including human genomic DNA, as well as single-stranded DNA (positive strand) including cDNA, single-stranded DNA (complementary strand) having a sequence complementary to the positive strand, and fragments thereof, and refers to DNA in which some biological information is contained in the sequence information of the bases constituting the DNA.
- the "gene” in question includes not only “genes” represented by a specific base sequence, but also nucleic acids encoding their homologues (i.e., homologs or orthologs), mutants such as gene polymorphisms, and derivatives.
- the "expression product” of a gene is a concept that encompasses the transcription product and translation product of the gene.
- a “transcription product” is RNA that is generated by transcription from a gene (DNA), and a “translation product” refers to a protein encoded by a gene that is translated and synthesized based on the RNA.
- atopic dermatitis refers to a disease whose main pathogenic cause is an itchy eczema that repeatedly worsens and remits, and many of its patients are said to have a predisposition to atopy.
- predisposition to atopy include i) family history or medical history (any or multiple of the following diseases: bronchial asthma, allergic rhinitis/conjunctivitis, and atopic dermatitis), or ii) a predisposition to easily produce IgE antibodies.
- severity of atopic dermatitis means the degree of progression of atopic dermatitis, and is classified according to the condition of the skin rash, for example, as no symptoms (healthy), slight, mild, moderate, or severe.
- the characteristics of the rash include erythema, edema/infiltration/papule (solid, serous), exudate/crust, scratch mark, lichenification, dryness, pruritus, prurigo nodules, scale (pityriasis, foliacea, membranous, etc.), blisters, pustules, erosion, ulcers, etc., and the severity is classified by, for example, the Eczema Area and Severity Index ("EASI" ⁇ Exp Dermatol, 2001; 10: 11-18.>), Investigator's Global Assessment (“IGA” ⁇ J Am Acad Dermatol, 2016; 74: 288-94.>), as well as the atopic dermatitis severity classification by the Atopic Dermatitis Severity Classification Committee of the Japanese Dermatological Association (JDJ ... 108: 1491-1496.), Severity Scoring of Atopic Dermatitis ("SCORAD" ⁇ Dermatology,1993; 186: 23-31.>, etc. are
- the EASI is a value of 0 to 72 calculated based on the four symptom scores of erythema, edema/infiltration/papule, scratch, and lichenification at each evaluation site, and the percentage (%) of the area of the above four symptoms in the entire evaluation site, with the head and neck, trunk, upper limbs, and lower limbs as evaluation sites.
- the head and neck EASI is a value of 0 to 7.2 calculated by multiplying the value calculated based on the four symptom scores of erythema, edema/infiltration/papule, scratch, and lichenification at the head and neck and the percentage (%) of the area of the above four symptoms in the head and neck by 0.1.
- the severity evaluation based on the head and neck EASI is also used as one of the guidelines for administration of atopic dermatitis treatment drugs.
- the severity of atopic dermatitis can be detected as “no symptoms”, “mild to moderate symptoms” and “severe symptoms”. However, it is preferable to distinguish between “no symptoms” and “mild to moderate symptoms”, and between “mild to moderate symptoms” and “severe symptoms”.
- “mild to moderate” includes mild and moderate symptoms (mild to moderate), for example, a head and neck EASI score of more than 0 and less than 2.4.
- “Severe” refers to severe, for example, a head and neck EASI score of 2.4 or more and 7.2 or less.
- No symptoms refers to a healthy person from the beginning, or a person in remission or near remission with no symptoms and at the same level as a healthy person.
- the range of scores serving as the basis for each evaluation is not limited to the above and can be determined as appropriate.
- detection of the severity of atopic dermatitis means clarifying the severity of atopic dermatitis, and can also be expressed as examination, measurement, judgment, or evaluation assistance. Note that in this specification, the terms “detection,” “examination,” “measurement,” “judgment,” or “evaluation” do not include a diagnosis of atopic dermatitis by a doctor.
- the gene to be measured (hereinafter also referred to as "target gene") is at least one selected from a total of 16 genes, including 11 genes shown in Table 1 and 5 genes shown in Table 2 below.
- the names (Gene Symbols) and Gene IDs of the genes shown in Tables 1 and 2 follow the Official Symbols and Gene IDs listed in NCBI ([www.ncbi.nlm.nih.gov/]).
- the target gene or its expression product is a marker for detecting the severity of atopic dermatitis, and the genes or their expression products shown in Table 1 are collectively referred to as the markers of Table 1, and the genes or their expression products shown in Table 2 are collectively referred to as the markers of Table 2.
- the marker of the present invention may be a gene shown in Table 1 or Table 2 below, or an expression product thereof, or a combination thereof.
- the marker of the present invention is a nucleic acid marker such as the DNA of the gene or the RNA that is its transcription product.
- the marker of the present invention is a protein marker that is a translation product of the gene.
- the marker of the present invention is a nucleic acid marker, more preferably an RNA marker.
- genes shown in Tables 1 and 2 include those consisting of nucleotide sequences registered with NCBI, as well as those consisting of sequences substantially identical to the registered sequences, so long as the genes themselves or expression products derived therefrom function as markers for detecting the severity of atopic dermatitis.
- the 11 types of genes shown in Table 1 are negative markers whose expression levels decrease stepwise with the severity of atopic dermatitis.
- the genes in Table 1 are genes related to epidermal function selected from genes whose expression decreases in mild to moderate patients compared to healthy subjects and in severe patients compared to mild to moderate patients, and have a higher accuracy of severity assessment than CCL17 (Gene ID: 6361), a gene encoding the TARC protein already known to reflect the severity of atopic dermatitis.
- the five genes shown in Table 2 are positive markers whose expression levels increase stepwise with the severity of atopic dermatitis.
- the genes in Table 2 are immune function-related genes selected from genes whose expression increases in mild to moderate patients compared to healthy subjects and in severe patients compared to mild to moderate patients, and are genes that have a higher accuracy of severity assessment than CCL17, a gene encoding the TARC protein that is already known to reflect the severity of atopic dermatitis. Therefore, the markers in Tables 1 and 2 make it possible to distinguish between healthy subjects and subjects with mild to moderate atopic dermatitis, and between subjects with mild to moderate atopic dermatitis and subjects with severe atopic dermatitis. Either the former negative marker or the latter positive marker may be used, or both may be used in combination.
- the method of the present invention for measuring genes or their expression products in a subject to detect the severity of atopic dermatitis in the subject includes a step of measuring the expression level of at least one gene selected from the above-mentioned target genes or its expression product in a biological sample collected from the subject.
- the subject for detecting the severity of atopic dermatitis in the subject of the present invention is not particularly limited in terms of sex, age, race, etc., and may include anyone from infants to the elderly.
- the subject is a human who needs or desires to detect the severity of atopic dermatitis.
- the subject is a human who has developed atopic dermatitis, a human who is suspected of developing atopic dermatitis, or a human who has a genetic predisposition to atopic dermatitis.
- the biological sample used in the present invention may be any cell, tissue, or biological material in which the expression of the target gene of the present invention changes depending on the severity of atopic dermatitis.
- Specific examples include organs, skin, blood, urine, saliva, sweat, stratum corneum, skin surface lipids (SSL), body fluids such as tissue exudates, serum and plasma prepared from blood, as well as stool, hair, etc., and preferably skin or skin surface lipids (SSL), and more preferably skin surface lipids (SSL).
- skin surface lipids refers to the fat-soluble fraction present on the surface of the skin, and is sometimes called sebum.
- SSL mainly contains secretions from exocrine glands such as sebaceous glands in the skin, and exists on the skin surface in the form of a thin layer that covers the skin surface.
- SSL contains RNA expressed in skin cells (see Patent Document 1).
- skin is a general term for the area including the epidermis, dermis, hair follicles, and tissues such as sweat glands, sebaceous glands, and other glands on the body surface, unless otherwise specified.
- any means used for recovering or removing SSL from the skin can be used.
- an SSL absorbent material, an SSL adhesive material, or an instrument for scraping SSL from the skin can be used.
- the SSL absorbent material or SSL adhesive material is not particularly limited as long as it has an affinity for SSL, and examples thereof include polypropylene and pulp. More detailed examples of procedures for collecting SSL from the skin include a method of absorbing SSL into a sheet-like material such as oil blotting paper or oil blotting film, a method of adhering SSL to a glass plate or tape, and a method of scraping SSL off and collecting it with a spatula, scraper, etc.
- an SSL absorbent material that has been previously impregnated with a highly lipid-soluble solvent may be used.
- the SSL absorbent material contains a low content of highly water-soluble solvents and water, since the adsorption of SSL is inhibited if the SSL absorbent material contains highly water-soluble solvents or water.
- the SSL absorbent material is preferably used in a dry state.
- the part of the skin from which the SSL is collected is not particularly limited, and may be any part of the body, such as the head, face, neck, trunk, hands, or feet, and is preferably a part where sebum is secreted in large amounts, such as the skin of the face.
- the part of the skin from which the SSL is collected may be either a rash area where atopic dermatitis has developed or a non-rash area where atopic dermatitis has not developed, but is preferably a rash area or a non-rash area near the rash area.
- the vicinity of the rash area refers to an area within 10 cm adjacent to the rash area.
- the RNA-containing SSL collected from the subject may be stored for a certain period of time. In order to minimize the degradation of the RNA contained in the SSL, it is preferable to store the collected SSL under low-temperature conditions as soon as possible after collection.
- the temperature conditions for storing the RNA-containing SSL in the present invention may be 0°C or lower, and are preferably -20°C ⁇ 20°C to -80°C ⁇ 20°C, more preferably -20°C ⁇ 10°C to -80°C ⁇ 10°C, even more preferably -20°C ⁇ 20°C to -40°C ⁇ 20°C, even more preferably -20°C ⁇ 10°C to -40°C ⁇ 10°C, even more preferably -20°C ⁇ 10°C, and even more preferably -20°C ⁇ 5°C.
- the period for storing the RNA-containing SSL under the low-temperature conditions is not particularly limited, but is preferably 12 months or less, for example, 6 hours or more and 12 months or less, more preferably 6 months or less, for example, 1 day or more and 6 months or less, even more preferably 3 months or less, for example, 3 days or more and 3 months or less.
- objects for measuring the expression level of a target gene or its expression product include cDNA artificially synthesized from RNA, DNA encoding that RNA, a protein encoded by that RNA, a molecule that interacts with the protein, a molecule that interacts with that RNA, or a molecule that interacts with that DNA.
- molecules that interact with RNA, DNA, or protein include DNA, RNA, proteins, polysaccharides, oligosaccharides, monosaccharides, lipids, fatty acids, and phosphorylations, alkylations, sugar adducts, etc. of these, as well as complexes of any of the above.
- the expression level comprehensively refers to the expression amount and activity of the gene or expression product.
- SSL is used as a biological sample, in which case the expression level of RNA contained in the SSL is analyzed, specifically, the RNA is converted to cDNA by reverse transcription, and then the cDNA or its amplification product is measured.
- RNA extraction reagent for extraction of RNA from SSL
- a method that is usually used for extracting or purifying RNA from a biological sample such as the phenol/chloroform method, the AGPC (acid guanidinium thiocyanate-phenol-chloroform extraction) method, or a method using columns such as TRIzol (registered trademark), RNeasy (registered trademark), or QIAzol (registered trademark), a method using special silica-coated magnetic particles, a method using Solid Phase Reversible Immobilization magnetic particles, or extraction using a commercially available RNA extraction reagent such as ISOGEN, can be used.
- a primer targeting a specific RNA to be analyzed may be used, but for more comprehensive nucleic acid storage and analysis, it is preferable to use a random primer.
- a general reverse transcriptase or reverse transcription reagent kit can be used.
- a highly accurate and efficient reverse transcriptase or reverse transcription reagent kit is used, and examples thereof include M-MLV Reverse Transcriptase and its variants, or commercially available reverse transcriptases or reverse transcription reagent kits, such as the PrimeScript (registered trademark) Reverse Transcriptase series (Takara Bio Inc.), the SuperScript (registered trademark) Reverse Transcriptase series (Thermo Scientific Inc.), and the like.
- the temperature of the extension reaction in the reverse transcription is preferably adjusted to 42° C. ⁇ 1° C., more preferably 42° C. ⁇ 0.5° C., and even more preferably 42° C. ⁇ 0.25° C., while the reaction time is preferably adjusted to 60 minutes or more, more preferably 80 to 120 minutes.
- the method for measuring the expression level can be selected from the following: PCR using DNA that hybridizes to these as a primer, nucleic acid amplification methods such as real-time RT-PCR, multiplex PCR, SmartAmp and LAMP, hybridization methods using nucleic acids that hybridize to these as a probe (DNA chips, DNA microarrays, dot blot hybridization, slot blot hybridization, Northern blot hybridization, etc.), methods for determining base sequences (sequencing), or a combination of these.
- a primer pair targeting a specific DNA to be analyzed may be used to amplify only one specific DNA, or multiple primer pairs may be used to simultaneously amplify multiple specific DNAs.
- the PCR is multiplex PCR.
- Multiplex PCR is a method of simultaneously amplifying multiple gene regions by simultaneously using multiple primer pairs in a PCR reaction system. Multiplex PCR can be performed using a commercially available kit (e.g., Ion AmpliSeq Transcriptome Human Gene Expression Kit; Life Technologies Japan, Inc., etc.).
- the temperature of the annealing and extension reaction in the PCR depends on the primers used and cannot be generally stated, but when the above multiplex PCR kit is used, it is preferably 62°C ⁇ 1°C, more preferably 62°C ⁇ 0.5°C, and even more preferably 62°C ⁇ 0.25°C. Therefore, in the PCR, the annealing and extension reaction are preferably performed in one step.
- the time of the annealing and extension reaction steps can be adjusted depending on the size of the DNA to be amplified, etc., but is preferably 14 to 18 minutes.
- the conditions of the denaturation reaction in the PCR can be adjusted depending on the DNA to be amplified, but are preferably 95 to 99°C for 10 to 60 seconds. Reverse transcription and PCR at the above-mentioned temperatures and times can be performed using a thermal cycler commonly used for PCR.
- the purification of the reaction products obtained by the PCR is preferably carried out by size separation of the reaction products.
- size separation By size separation, the target PCR reaction products can be separated from primers and other impurities contained in the PCR reaction solution.
- Size separation of DNA can be carried out, for example, by using a size separation column, a size separation chip, magnetic beads that can be used for size separation, etc.
- a preferred example of magnetic beads that can be used for size separation is Solid Phase Reversible Immobilization (SPRI) magnetic beads such as Ampure XP.
- SPRI Solid Phase Reversible Immobilization
- the purified PCR reaction products may be subjected to further processing required for subsequent quantitative analysis.
- the purified PCR reaction products may be prepared in an appropriate buffer solution, the PCR primer regions contained in the PCR-amplified DNA may be cleaved, or an adapter sequence may be further added to the amplified DNA.
- the purified PCR reaction products may be prepared in a buffer solution, the PCR primer sequences may be removed from the amplified DNA, and adapter ligation may be performed, and the resulting reaction products may be amplified as necessary to prepare a library for quantitative analysis.
- a probe DNA is labeled with a radioisotope, a fluorescent substance, etc., and then the resulting labeled DNA is hybridized with RNA derived from a biological sample that has been transferred to a nylon membrane or the like in a standard manner.
- RNA derived from a biological sample that has been transferred to a nylon membrane or the like in a standard manner.
- the resulting double strand of labeled DNA and RNA is then measured by detecting a signal derived from the label.
- cDNA is prepared from RNA derived from a biological sample in a standard manner, and then a pair of primers (a positive strand that binds to the above cDNA (-strand), and a reverse strand that binds to the + strand) that have been prepared so that the target gene of the present invention can be amplified using this as a template are hybridized with this. Then, PCR is performed in a standard manner, and the resulting amplified double-stranded DNA is detected.
- the amplified double-stranded DNA can be detected by a method in which the above PCR is performed using primers that have been labeled in advance with RI, a fluorescent substance, or the like, to detect the labeled double-stranded DNA produced.
- an array having at least one type of nucleic acid (cDNA or DNA) derived from the target gene of the present invention immobilized on a support is used, labeled cDNA or cRNA prepared from mRNA is bound to the microarray, and the label on the microarray is detected, thereby measuring the expression level of mRNA.
- the nucleic acid immobilized on the array may be any nucleic acid that hybridizes specifically (i.e., substantially only to the target nucleic acid) under stringent conditions.
- the stringent conditions may be washing conditions of about "1xSSC, 0.1% SDS, 37°C", more stringent hybridization conditions may be about "0.5xSSC, 0.1% SDS, 42°C", and even more stringent hybridization conditions may be about "0.1xSSC, 0.1% SDS, 65°C”. Hybridization conditions are described in J. Sambrook et al., Molecular Cloning: A Laboratory Manual, Third Edition, Cold Spring Harbor Laboratory Press (2001), etc.
- RNA expression can be quantified based on the number of reads (read count) generated by sequencing.
- the probe or primer used in the above measurement i.e., a primer for specifically recognizing and amplifying the target gene of the present invention or a nucleic acid derived therefrom, or a probe for specifically detecting the RNA or a nucleic acid derived therefrom, corresponds to this, and these can be designed based on the base sequence constituting the target gene.
- “specifically recognize” means that the detected substance or product can be determined to be the gene or a nucleic acid derived therefrom, for example, in the Northern blot method, so that substantially only the target gene of the present invention or a nucleic acid derived therefrom can be detected, or, for example, in the RT-PCR method, so that substantially only the nucleic acid is amplified.
- a DNA consisting of a base sequence constituting the target gene of the present invention or an oligonucleotide containing a certain number of nucleotides complementary to its complementary strand can be used.
- complementary strand refers to one strand of a double-stranded DNA consisting of A:T (U in the case of RNA) and G:C base pairs, with respect to the other strand.
- “complementary” does not necessarily mean that the sequence is completely complementary in the certain number of consecutive nucleotide regions, but rather that the sequence has an identity of preferably 80% or more, more preferably 90% or more, and even more preferably 95% or more.
- the identity of the base sequence can be determined by an algorithm such as BLAST.
- such an oligonucleotide When used as a primer, such an oligonucleotide may be capable of specific annealing and chain elongation, and may generally have a chain length of, for example, 10 bases or more, preferably 15 bases or more, more preferably 20 bases or more, and for example, 100 bases or less, preferably 50 bases or less, more preferably 35 bases or less.
- such an oligonucleotide When used as a probe, such an oligonucleotide may be capable of specific hybridization, and may have at least a part or all of the sequence of DNA (or its complementary strand) consisting of the base sequence constituting the target gene of the present invention, and may have a chain length of, for example, 10 bases or more, preferably 15 bases or more, and for example, 100 bases or less, preferably 50 bases or less, more preferably 25 bases or less.
- the "oligonucleotide” may be DNA or RNA, and may be either synthetic or natural.
- the probe used in hybridization is usually labeled.
- a molecule that interacts with the protein a molecule that interacts with RNA, or a molecule that interacts with DNA
- methods such as protein chip analysis, immunoassays (e.g., ELISA, etc.), mass spectrometry (e.g., LC-MS/MS, MALDI-TOF/MS), the one-hybrid method (PNAS 100, 12271-12276 (2003)), and the two-hybrid method (Biol. Reprod. 58, 302-311 (1998)) can be used, and can be appropriately selected depending on the subject.
- the measurement is carried out by contacting a biological sample with an antibody that specifically recognizes the expression product of the present invention, specifically an antibody that recognizes a structural characteristic site (epitope) that can distinguish the expression product protein from other proteins, detecting the polypeptide or protein in the sample that binds to the antibody, and measuring its level.
- an antibody that specifically recognizes the expression product of the present invention specifically an antibody that recognizes a structural characteristic site (epitope) that can distinguish the expression product protein from other proteins, detecting the polypeptide or protein in the sample that binds to the antibody, and measuring its level.
- the primary antibody is labeled with a radioisotope, a fluorescent substance, an enzyme, or the like as a secondary antibody, and the primary antibody is labeled with the secondary antibody, and the signal derived from the labeling substance is measured with a radiation measuring device, a fluorescence detector, or the like.
- the antibody against the translation product may be a polyclonal antibody or a monoclonal antibody. These antibodies can be produced according to known methods. Specifically, polyclonal antibodies can be obtained by immunizing a non-human animal such as a rabbit with a protein expressed in E.
- monoclonal antibodies can be obtained from hybridoma cells prepared by immunizing a non-human animal such as a mouse with a protein expressed and purified in E. coli or a partial polypeptide of the protein according to a conventional method, and fusing the resulting spleen cells with myeloma cells.
- Monoclonal antibodies may also be prepared using phage display (Griffiths, AD; Duncan, AR, Current Opinion in Biotechnology, Volume 9, Number 1, February 1998, pp. 102-108(7)).
- the expression level of the target gene of the present invention or its expression product in a biological sample collected from a subject is measured, and the severity of atopic dermatitis is detected based on the expression level.
- the detection may be performed by comparing the measured expression level of the target gene of the present invention or its expression product with a control level.
- the read count value which is data on the expression level
- the RPM value obtained by correcting the read count value for the difference in the total number of reads between samples
- the count value corrected using DESeq2 Love MI et al. Genome Biol. 2014) (Normalized count value) or the logarithmic value with base 2 with an integer 1 added (Log 2 (count+1) value) as an index.
- fragments per kilobase of exon per million reads which is a common quantitative value for RNA-seq, are preferably used as an index.
- the value may be a value calculated by the FPKM, reads per kilobase of exon per million reads mapped (RPKM), transcripts per million (TPM), or the like. It may also be a signal value obtained by a microarray method and its corrected value.
- control level refers to, for example, the expression level of the target gene or its expression product in healthy individuals when detecting mild to moderate patients, and in mild to moderate patients when detecting severe patients.
- the expression levels of healthy individuals, mild to moderate patients, and severe patients may be statistical values (e.g., average values, etc.) of the expression levels of the gene or its expression product measured from a group of healthy individuals, mild to moderate patients, and severe patients. When there are multiple target genes, it is preferable to determine the control level for each gene or its expression product.
- the severity of atopic dermatitis in the present invention can also be detected by comparing the expression level of the target gene or its expression product of the present invention with the cutoff value (reference value) of each gene or its expression product.
- the cutoff value can be determined appropriately based on statistical values such as the average value and standard deviation of the expression levels based on the expression levels of the target gene or its expression product in healthy individuals, mildly ill patients, moderately ill patients, and severely ill patients, which are obtained in advance as reference data.
- the method for determining the cutoff value is not particularly limited, and can be determined according to a known method. For example, it can be obtained from a receiver operating characteristic curve (ROC).
- ROC receiver operating characteristic curve
- the vertical axis plots the probability of a positive result in a positive patient (sensitivity or true positive rate)
- the horizontal axis plots the value obtained by subtracting the probability of a negative result in a negative patient (specificity) from 1 (false positive rate).
- the threshold value at the point (Youden index) where "true positive rate (sensitivity)” - “false positive rate (1-specificity)” is maximum can be used as the cutoff value (reference value).
- a cutoff value (reference value) for distinguishing between two groups of different severity is determined in advance, and if the expression level of the target gene or its expression product in a biological sample derived from a subject is equal to or higher than the cutoff value (reference value) for each gene or its expression product, the group is determined to be less severe, and if the expression level is equal to or lower than the reference value, the group is determined to be more severe.
- cutoff values for distinguishing between two groups of different severity for the genes shown in Table 2 are determined in advance, and if the expression level of the target gene or its expression product in a biological sample derived from a subject is below the cutoff value (reference value) for each gene or its expression product, the group is determined to be less severe, and if the expression level is above the reference value, the group is determined to be more severe.
- the average values (AUC3) of the areas under the curve (AUC1 and AUC2) of the ROC curves for discriminating between the two groups are all higher than the AUC3 when the CCL17 gene encoding the TARC protein, which is known as a severity marker, is used, and the discrimination accuracy is high.
- the cutoff value can be determined by the threshold value at the point (Youden index) where the "true positive rate (sensitivity)” - “false positive rate (1 - specificity)” is maximum for the “true positive rate (sensitivity)” and “false positive rate (1 - specificity)” shown in the ROC curve.
- Table 3 shows an example of each reference value when discriminating between two groups, healthy and mild to moderate atopic dermatitis, and between two groups, mild to moderate atopic dermatitis and severe atopic dermatitis, using 16 genes, but the reference values are not limited to these and can be determined appropriately.
- the expression level of a target gene or its expression product in a subject is measured, and the measured expression level is compared with a preset reference value, thereby detecting the severity of atopic dermatitis in the subject.
- the reference value can be determined in advance based on the relationship between the severity of atopic dermatitis (the severity level of atopic dermatitis classified based on the score value related to the severity of atopic dermatitis or the score value related to the severity of atopic dermatitis) and the expression level of the target gene or its expression product.
- a certain population can be divided into a plurality of groups with different severity levels based on the severity of atopic dermatitis, and a reference value for determining whether or not the subject belongs to each group can be determined with reference to the statistical value (e.g., the average value) of the expression level of the target gene or its expression product in each group.
- a plurality of types of markers are used as the target gene or its expression product, it is preferable to determine the reference value for each marker.
- the population may be any of a group of patients with atopic dermatitis, a group of healthy subjects and a group of patients with atopic dermatitis, and a group of patients with a specific severity of atopic dermatitis.
- groups may be created by age, generation, sex, or race according to the subjects to be detected.
- groups used for calculating the reference value include a mild patient group (mild group), a moderate patient group (moderate group), a mild and moderate patient group (mild-moderate group), a severe patient group (severe group), etc.
- a healthy control group (a group without symptoms of atopic dermatitis) may also be included.
- the negative marker When the negative marker is used, the lower the expression level, the higher the severity of the subject's atopic dermatitis is detected. On the other hand, when the positive marker is used, the higher the expression level, the higher the severity of the subject's atopic dermatitis is detected.
- the expression levels of a target gene or its expression product in a subject are measured at different times, and the measured expression levels of the target gene or its expression product are compared to detect a change in the severity (e.g., exacerbation or amelioration) of the subject's atopic dermatitis.
- an increase in its expression level over time represents a decrease in the severity of the subject's atopic dermatitis
- a decrease in its expression level over time represents an increase in the severity of the subject's atopic dermatitis.
- the expression level of the target gene or its expression product in the same subject in a past measurement is used as a reference value.
- the severity of the subject's atopic dermatitis may be determined by a conventional method during the past measurement. In that case, when the expression level of the negative marker measured from the subject is higher or lower than the reference value, the severity of the subject's atopic dermatitis may be detected as being lower or higher than the severity of the atopic dermatitis in the past measurement.
- an increase in its expression level over time represents an increase in the severity of the subject's atopic dermatitis
- a decrease in its expression level over time represents a decrease in the severity of the subject's atopic dermatitis.
- the expression level of the target gene or its expression product in the same subject in a previous measurement is used as a reference value.
- the severity of the subject's atopic dermatitis may be determined by a conventional method during the previous measurement. In that case, when the expression level of the positive marker measured from the subject is higher or lower than the reference value, the severity of the subject's atopic dermatitis can be detected as being higher or lower than the severity of the atopic dermatitis in the previous measurement.
- the expression level of the target gene or its expression product derived from the subject is preferably 91% or less, more preferably 83% or less, and even more preferably 77% or less of the reference value
- the expression level of the target gene or its expression product can be determined to be lower than the reference value
- the expression level of the target gene or its expression product derived from the subject is preferably 110% or more, more preferably 120% or more, and even more preferably 130% or more of the reference value
- the expression level of the target gene or its expression product can be determined to be higher than the reference value.
- the difference between the expression level of the target gene or its expression product derived from the subject and the reference value can be determined, for example, by whether or not the two are statistically significantly different.
- the expression level of each target gene or its expression product is compared with the reference value, and the severity of atopic dermatitis can be detected by examining whether or not a certain percentage, for example, 50% or more, preferably 70% or more, more preferably 90% or more, and even more preferably 100% of the expression levels of the target genes or their expression products are different from the reference value.
- the expression level of a target gene or its expression product in a subject is measured, and the expression level is substituted into a discriminant (prediction model) for detecting the severity of atopic dermatitis, thereby detecting the severity of atopic dermatitis in the subject.
- a discriminant prediction model
- a discriminant can be constructed by machine learning using measured values of the expression levels of target genes or their expression products from patients with atopic dermatitis of different severity (e.g., mild patients, mild-moderate patients, moderate patients, severe patients) and healthy individuals as teacher samples, the expression levels of at least one or more target genes or their expression products obtained from each person in the teacher samples as explanatory variables, and the severity of atopic dermatitis of each person (e.g., mild, mild-moderate, moderate, severe) or no symptoms (healthy) as the objective variable.
- the expression levels of the target genes or their expression products in the subject are then measured, and the severity of atopic dermatitis in the subject can be detected by substituting the expression levels into the discriminant.
- dimensionality can be reduced by principal component analysis (PCA) and the main components can be used as explanatory variables.
- PCA principal component analysis
- the test kit for detecting the severity of atopic dermatitis of the present invention contains a test reagent for measuring the expression level of the target gene of the present invention or its expression product in a biological sample separated from a patient.
- the test kit includes a reagent for nucleic acid amplification or hybridization containing an oligonucleotide (e.g., a primer for PCR) that specifically binds (hybridizes) to the target gene of the present invention or a nucleic acid derived therefrom, or a reagent for immunological measurement containing an antibody that recognizes the expression product (protein) of the target gene of the present invention.
- an oligonucleotide e.g., a primer for PCR
- test kit can be obtained by a known method as described above.
- the test kit may also include labeling reagents, buffer solutions, color-developing substrates, secondary antibodies, blocking agents, equipment necessary for the test, control reagents used as positive controls and negative controls, and tools for collecting biological samples (e.g., oil blotting films for collecting SSL).
- a method for measuring a gene or its expression product in a subject comprising a step of measuring the expression level of at least one gene or its expression product selected from a group of 16 genes consisting of C1QB, DIAPH1, LCE1A, CTSV, CTSZ, KRT72, SPINK5, KRT23, KLK5, LCE1B, SPRR1A, PKP1, KRT74, APRT, KRT25 and S100B in a biological sample collected from the subject in order to detect the severity of atopic dermatitis in the subject.
- a method for detecting the severity of atopic dermatitis in a subject comprising a step of measuring the expression level of at least one gene or its expression product selected from a group of 16 genes consisting of C1QB, DIAPH1, LCE1A, CTSV, CTSZ, KRT72, SPINK5, KRT23, KLK5, LCE1B, SPRR1A, PKP1, KRT74, APRT, KRT25 and S100B in a biological sample collected from the subject.
- ⁇ 3> The method according to ⁇ 1> or ⁇ 2>, wherein the gene is at least one gene selected from a group of nine genes consisting of C1QB, DIAPH1, LCE1A, CTSV, CTSZ, KRT72, SPINK5, KRT23 and KLK5, and preferably C1QB.
- ⁇ 4> The method according to ⁇ 1> or ⁇ 2>, wherein the gene is at least one gene selected from a group of 11 genes consisting of LCE1A, CTSV, KRT72, SPINK5, KRT23, KLK5, LCE1B, SPRR1A, PKP1, KRT74, and KRT25, preferably a group of six genes consisting of LCE1A, CTSV, KRT72, SPINK5, KRT23, and KLK5, and the lower the expression level of the gene or its expression product, the higher the severity of the atopic dermatitis of the subject.
- the gene is at least one gene selected from a group of 11 genes consisting of LCE1A, CTSV, KRT72, SPINK5, KRT23, KLK5, LCE1B, SPRR1A, PKP1, KRT74, and KRT25, preferably a group of six genes consisting of LCE1A, CTSV, KRT72, SPINK5, KRT23, and KLK5, and the lower
- ⁇ 5> The method of ⁇ 4>, wherein a reference value for discriminating between two groups with different severity is determined in advance, and if the expression level of the gene or its expression product of the atopic dermatitis patient is equal to or higher than the reference value, the patient is classified as a less severe group, and if the expression level is equal to or lower than the reference value, the patient is classified as a more severe group.
- ⁇ 6> The method of ⁇ 1> or ⁇ 2>, wherein the gene is at least one gene selected from a group of five genes consisting of C1QB, DIAPH1, CTSZ, APRT and S100B, preferably a group of three genes consisting of C1QB, DIAPH1 and CTSZ, and a higher expression level of the gene or its expression product indicates a higher severity of the atopic dermatitis of the subject.
- ⁇ 7> The method of ⁇ 6>, wherein a reference value for discriminating between two groups with different severity is determined in advance, and if the expression level of the gene or its expression product of the atopic dermatitis patient is below the reference value, the patient is classified as a group with a less severe condition, and if the expression level is above the reference value, the patient is classified as a group with a more severe condition.
- ⁇ 8> The method according to any one of ⁇ 1> to ⁇ 7>, wherein the severity is one or more selected from the group consisting of no symptoms (healthy), mild to moderate, and severe.
- ⁇ 9> The method according to ⁇ 5> or ⁇ 7>, wherein the two groups having different severity are a group of healthy subjects and a group of subjects with mild to moderate atopic dermatitis, or a group of subjects with mild to moderate atopic dermatitis and a group of subjects with severe atopic dermatitis.
- ⁇ 10> The method of ⁇ 1> or ⁇ 2>, in which the severity of atopic dermatitis in a subject is detected by substituting a measured value of the expression level of a target gene or its expression product in a subject into a discriminant constructed using measured values of the expression level of a target gene or its expression product from atopic dermatitis patients with different severity and the expression level of a target gene or its expression product from a healthy subject as teacher samples.
- ⁇ 11> The method according to ⁇ 10>, wherein the severity is one or more selected from mild, mild-moderate, moderate and severe.
- ⁇ 12> The method of ⁇ 10> or ⁇ 11>, wherein the discriminant equation is constructed by machine learning using the expression levels of at least one or more target genes or their expression products obtained from each person in the teacher sample as explanatory variables, and the severity of atopic dermatitis and the absence of symptoms (healthy state) of each person as objective variables.
- the algorithm used for the machine learning is selected from a random forest, a support vector machine with a linear kernel (SVM linear), a support vector machine with an rbf kernel (SVM rbf), a neural net, a generalized linear model, a regularized linear discriminant analysis, and a regularized logistic regression.
- ⁇ 14> The method according to any one of ⁇ 1> to ⁇ 13>, wherein the expression level of the gene or its expression product is an expression amount of mRNA.
- the expression level of the gene or its expression product is an expression amount of mRNA.
- the gene or its expression product is RNA contained in lipids on the skin surface of the subject.
- Any of the methods ⁇ 1> to ⁇ 15>, wherein the severity is a severity classification based on the Head and Neck EASI.
- a test kit for detecting the severity of atopic dermatitis which is used in any one of the methods ⁇ 1> to ⁇ 16>, comprising an oligonucleotide that specifically hybridizes with the gene or a nucleic acid derived therefrom, or an antibody that recognizes an expression product of the gene.
- ⁇ 18> Use of at least one gene or its expression product selected from a group of 16 genes consisting of C1QB, DIAPH1, LCE1A, CTSV, CTSZ, KRT72, SPINK5, KRT23, KLK5, LCE1B, SPRR1A, PKP1, KRT74, APRT, KRT25 and S100B, derived from a biological sample collected from a subject, as a marker for the severity of atopic dermatitis.
- ⁇ 19> The use of ⁇ 18>, wherein the gene or its expression product is at least one gene or its expression product selected from the group of nine genes consisting of C1QB, DIAPH1, LCE1A, CTSV, CTSZ, KRT72, SPINK5, KRT23, or KLK5, preferably C1QB or its expression product.
- ⁇ 20> The use of ⁇ 18> or ⁇ 19>, wherein the gene or its expression product is mRNA derived from skin surface lipids collected from the subject.
- ⁇ 21> The use of any one of ⁇ 18> to ⁇ 20>, wherein the severity is based on the Head and Neck EASI.
- Example 1 Detection of severity of atopic dermatitis using RNA extracted from SSL 1. Diagnosis of mild to moderate atopic dermatitis patients and SSL collection Fourteen healthy subjects (25-57 years old, male) and 29 adults with atopic skin (AD) (23-56 years old, male) were subjects. The atopic dermatitis patients were diagnosed by a dermatologist as having mild and moderate atopic dermatitis. The head and neck EASI score (Hanifin et al. Exp dermatol.10, 2001) was used for diagnosis, and the head and neck EASI score of the patients was 0.1 to 1.8 (average 0.50).
- Sebum was collected from the entire face of each subject using a single piece of oil blotting film (polypropylene, 5.0 cm x 8.0 cm, 3M), which was then transferred to a vial and stored at -80°C for approximately one month until use in RNA extraction.
- oil blotting film polypropylene, 5.0 cm x 8.0 cm, 3M
- Sebum was collected from the entire face of each subject using a sheet of oil blotting film (polypropylene, 5.0 cm x 8.0 cm, 3M Co.), and the oil blotting film was transferred to a vial and stored at -80°C for about one month until it was used for RNA extraction.
- oil blotting film polypropylene, 5.0 cm x 8.0 cm, 3M Co.
- RNA preparation and sequencing The oil blotting film from which sebum was collected in 1) and 2) above was cut to an appropriate size, and RNA was transferred to the aqueous layer using QIAzol Lysis Reagent (Qiagen) according to the attached protocol. RNA was extracted from the aqueous layer using a commercially available RNA extraction kit using a spin column for RNA extraction according to the attached protocol. The extracted RNA was reverse transcribed at 42°C for 90 minutes using SuperScript VILO cDNA Synthesis kit (Life Technologies Japan, Inc.) to synthesize cDNA. The random primers included in the kit were used as primers for the reverse transcription reaction. A library containing DNA derived from the 20802 gene was prepared from the obtained cDNA by multiplex PCR.
- RNA Expression Analysis 1 Based on the SSL-derived RNA expression levels (normalized count values) of healthy subjects and mild to moderate AD subjects measured in i) above, RNAs (expression-varying genes) with a p-value corrected value (FDR) of less than 0.1 in mild to moderate AD compared to healthy subjects were identified. As a result, 1424 types of RNA were decreased (DOWN) in mild to moderate AD, and 1966 types of RNA were increased (UP) in mild to moderate AD.
- FDR p-value corrected value
- RNA Expression Analysis 2 Based on the SSL-derived RNA expression levels (normalized count values) of mild to moderate AD and severe AD measured in i) above, RNAs (expression-varying genes) whose p-value corrected value (FDR) in severe AD was less than 0.1 by likelihood ratio test compared to mild to moderate AD were identified. As a result, 1436 types of RNA were decreased (DOWN) in severe AD, and 1417 types of RNA were increased (UP) in severe AD.
- genes whose expression increases stepwise with severity Genes corresponding to both the 1966 genes whose expression increased in mild to moderate AD compared to healthy subjects identified in ii) above and the 1417 genes whose expression increased in severe AD compared to mild to moderate AD identified in iii) above were extracted, and 34 genes were found to be relevant.
- the 34 genes are genes whose expression may increase stepwise with the severity of AD, that is, genes whose expression level can detect the severity of atopic dermatitis.
- 9 genes were extracted as genes related to immune function based on information such as genes constituting related reaction pathways and GO terms, as well as genes reported in literature known to those skilled in the art. Among them was CCL17, a gene encoding the TARC protein, which is already known to reflect the severity of AD. These 9 genes were used as candidates to select genes with higher discrimination accuracy in the evaluation in the following 5).
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Sustainable Development (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023076892 | 2023-05-08 | ||
| JP2023-076892 | 2023-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2024232368A1 true WO2024232368A1 (ja) | 2024-11-14 |
Family
ID=93430164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2024/017017 Ceased WO2024232368A1 (ja) | 2023-05-08 | 2024-05-07 | アトピー性皮膚炎の重症度の検出方法 |
Country Status (2)
| Country | Link |
|---|---|
| JP (3) | JP7767500B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2024232368A1 (cg-RX-API-DMAC7.html) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021221138A1 (ja) * | 2020-05-01 | 2021-11-04 | 花王株式会社 | アトピー性皮膚炎の検出方法 |
| JP2022016416A (ja) * | 2020-07-10 | 2022-01-21 | 花王株式会社 | アトピー性皮膚炎の重症度の検出方法 |
| JP2022049694A (ja) * | 2020-09-16 | 2022-03-29 | 花王株式会社 | 乳幼児アトピー性皮膚炎の検出方法 |
| JP2022087074A (ja) * | 2020-11-30 | 2022-06-09 | 花王株式会社 | アトピー性皮膚炎の症度の検出方法 |
-
2024
- 2024-05-07 WO PCT/JP2024/017017 patent/WO2024232368A1/ja not_active Ceased
- 2024-05-07 JP JP2024075513A patent/JP7767500B2/ja active Active
-
2025
- 2025-10-29 JP JP2025182297A patent/JP2026012310A/ja active Pending
- 2025-12-23 JP JP2025278912A patent/JP2026040607A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021221138A1 (ja) * | 2020-05-01 | 2021-11-04 | 花王株式会社 | アトピー性皮膚炎の検出方法 |
| JP2022016416A (ja) * | 2020-07-10 | 2022-01-21 | 花王株式会社 | アトピー性皮膚炎の重症度の検出方法 |
| JP2022049694A (ja) * | 2020-09-16 | 2022-03-29 | 花王株式会社 | 乳幼児アトピー性皮膚炎の検出方法 |
| JP2022087074A (ja) * | 2020-11-30 | 2022-06-09 | 花王株式会社 | アトピー性皮膚炎の症度の検出方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024161911A (ja) | 2024-11-20 |
| JP2026012310A (ja) | 2026-01-23 |
| JP7767500B2 (ja) | 2025-11-11 |
| JP2026040607A (ja) | 2026-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7849812B2 (ja) | パーキンソン病の検出方法 | |
| WO2021221138A1 (ja) | アトピー性皮膚炎の検出方法 | |
| JP7743217B2 (ja) | アトピー性皮膚炎の重症度の検出方法 | |
| JP7762549B2 (ja) | アトピー性皮膚炎の症度変化の検出方法 | |
| JP7743239B2 (ja) | 乳幼児アトピー性皮膚炎の検出方法 | |
| JP7743475B2 (ja) | アトピー性皮膚炎の検出方法 | |
| JP7743289B2 (ja) | アトピー性皮膚炎の症度の検出方法 | |
| JP7767500B2 (ja) | アトピー性皮膚炎の重症度の検出方法 | |
| WO2022220298A1 (ja) | 乳幼児おむつ皮膚炎の症度の検出方法 | |
| JP7743474B2 (ja) | 乳幼児アトピー性皮膚炎の検出方法 | |
| JP7847451B2 (ja) | アトピー性皮膚炎による皮膚痒みの症度悪化の検出方法 | |
| JP7847450B2 (ja) | アトピー性皮膚炎の症度悪化の検出方法 | |
| JP7750481B2 (ja) | 内臓脂肪面積の検出方法 | |
| WO2022220299A1 (ja) | 乳幼児顔湿疹の症度の検出方法 | |
| JP2023073134A (ja) | ホットフラッシュの検出方法 | |
| JP2023073135A (ja) | 更年期障害の重症度の検出方法 | |
| JP2023045067A (ja) | 不眠の検出方法 | |
| JP2023048810A (ja) | 慢性ストレスレベルの検出方法 | |
| JP2023048811A (ja) | 疲労の検出方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 24803477 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 24803477 Country of ref document: EP Kind code of ref document: A1 |